Cargando…

Impact of the new FIGO 2013 classification on prognosis of stage I epithelial ovarian cancers

PURPOSE: The stage of disease is one of the strongest prognostic factors in epithelial ovarian cancer. The International Federation of Gynecology and Obstetrics (FIGO) classification was revised in 2013; stage IC was subdivided into IC1 (intraoperative surgical spill), IC2 (capsule rupture before su...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sartorius, Céline Montavon, Mirza, Uzma, Schötzau, Andreas, Mackay, Gillian, Fink, Daniel, Hacker, Neville F, Heinzelmann-Schwarz, Viola
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2018
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6199966/ https://www.ncbi.nlm.nih.gov/pubmed/30410404 http://dx.doi.org/10.2147/CMAR.S174777

Ejemplares similares

Fibrin-thrombin sealant does not reduce lymphocele formation in patients with inguinofemoral lymphadenectomy for vulvar cancer
por: Saner, Flurina AM, et al.
Publicado: (2019)

ABO blood groups as a prognostic factor for recurrence in ovarian and vulvar cancer
por: Montavon Sartorius, Céline, et al.
Publicado: (2018)

Survival analysis of revised 2013 FIGO staging classification of epithelial ovarian cancer and comparison with previous FIGO staging classification
por: Paik, E Sun, et al.
Publicado: (2015)

L1CAM is not a reliable predictor for lymph node metastases in endometrial cancer, but L1CAM positive patients benefit from radiotherapy
por: Zeiter, Deborah, et al.
Publicado: (2021)

Hormone Receptor Expression in Primary and Recurrent High-Grade Serous Ovarian Cancer and Its Implications in Early Maintenance Treatment
por: Vetter, Marcus, et al.
Publicado: (2022)

Diaphragmatic smears are not of additional benefit in the detection of peritoneal spread in gynecological cancers
por: Montavon, Celine, et al.
Publicado: (2018)

Naturally occurring anti-glycan antibodies binding to Globo H-expressing cells identify ovarian cancer patients
por: Pochechueva, Tatiana, et al.
Publicado: (2017)

Outcome in serous ovarian cancer is not associated with LATS expression
por: Montavon, Céline, et al.
Publicado: (2019)

Reliable in vitro studies require appropriate ovarian cancer cell lines
por: Jacob, Francis, et al.
Publicado: (2014)

Targeting the ROR1 and ROR2 receptors in epithelial ovarian cancer inhibits cell migration and invasion
por: Henry, Claire, et al.
Publicado: (2015)

A Suggested Modification to FIGO Stage IV Epithelial Ovarian Cancer
por: Métairie, Marie, et al.
Publicado: (2023)

The FIGO Ovulatory Disorders Classification System
por: Munro, Malcolm G, et al.
Publicado: (2022)

The FIGO ovulatory disorders classification system
por: Munro, Malcolm G., et al.
Publicado: (2022)

Perioperative management with ferric carboxymaltose and tranexamic acid to reduce transfusion rate in gynaecological carcinoma surgery (TRANAFER-Study): study protocol for a single-blind, monocentre, randomised trial
por: Amstad, Gabriela, et al.
Publicado: (2022)

An interdisciplinary team-training protocol for robotic gynecologic surgery improves operating time and costs: analysis of a 4-year experience in a university hospital setting
por: Vigo, Francesco, et al.
Publicado: (2021)

Expression of GBGT1 is epigenetically regulated by DNA methylation in ovarian cancer cells
por: Jacob, Francis, et al.
Publicado: (2014)

Blood Plasma-Derived Anti-Glycan Antibodies to Sialylated and Sulfated Glycans Identify Ovarian Cancer Patients
por: Pochechueva, Tatiana, et al.
Publicado: (2016)

FIGO staging in ovarian carcinoma and histological subtypes
por: Kehoe, Sean
Publicado: (2020)

Comparison of 2D 4K vs. 3D HD laparoscopic imaging systems using a pelvitrainer model: a randomized controlled study
por: Zwimpfer, Tibor A., et al.
Publicado: (2021)

Loss of Secreted Frizzled-Related Protein 4 Correlates with an Aggressive Phenotype and Predicts Poor Outcome in Ovarian Cancer Patients
por: Jacob, Francis, et al.
Publicado: (2012)

A retrospective analysis for investigating the relationship between FIGO stage IVA/IVB and cytoreductive surgery with prognosis in epithelial ovarian cancer
por: Liu, Hong, et al.
Publicado: (2023)

Tomm34 is commonly expressed in epithelial ovarian cancer and associates with tumour type and high FIGO stage
por: Muller, Petr, et al.
Publicado: (2019)

Careful Selection of Reference Genes Is Required for Reliable Performance of RT-qPCR in Human Normal and Cancer Cell Lines
por: Jacob, Francis, et al.
Publicado: (2013)

Tissue glycomics distinguish tumour sites in women with advanced serous adenocarcinoma
por: Anugraham, Merrina, et al.
Publicado: (2017)

A distinct molecular profile associated with mucinous epithelial ovarian cancer
por: Heinzelmann-Schwarz, V A, et al.
Publicado: (2006)

Ovarian cancer: imaging in treatment selection and planning with FIGO update
por: Sala, Evis
Publicado: (2014)

Ovarian cancer: imaging in treatment selection and planning with FIGO update
por: Sala, Evis
Publicado: (2015)

Risk stratification of abdominopelvic failure for FIGO stage III epithelial ovarian cancer patients: implications for adjuvant radiotherapy
por: Chang, Jee Suk, et al.
Publicado: (2013)

Prerequisites to improve surgical cytoreduction in FIGO stage III/IV epithelial ovarian cancer and subsequent clinical ramifications
por: de Jong, Diederick, et al.
Publicado: (2023)

Comparison of printed glycan array, suspension array and ELISA in the detection of human anti-glycan antibodies
por: Pochechueva, Tatiana, et al.
Publicado: (2011)

Should MMMT still be treated with adjuvant taxane-based combination chemotherapy?
por: Heinzelmann-Schwarz, Viola, et al.
Publicado: (2020)

Prognostic Value of Residual Disease after Interval Debulking Surgery for FIGO Stage IIIC and IV Epithelial Ovarian Cancer
por: Rutten, Marianne J., et al.
Publicado: (2015)

Gene Set-Based Functionome Analysis of Pathogenesis in Epithelial Ovarian Serous Carcinoma and the Molecular Features in Different FIGO Stages
por: Chang, Chia-Ming, et al.
Publicado: (2016)

Nivolumab in chemotherapy-resistant cervical cancer: report of a vulvitis as a novel immune-related adverse event and molecular analysis of a persistent complete response
por: Baettig, Florence, et al.
Publicado: (2019)

Meta-Analysis of Microarray Data Identifies GAS6 Expression as an Independent Predictor of Poor Survival in Ovarian Cancer
por: Buehler, Michelle, et al.
Publicado: (2013)

FIGO's staging classification for cancer of the ovary, fallopian tube, and peritoneum: abridged republication
por: Prat, Jaime
Publicado: (2015)

Risk Stratification of Endometrial Cancer Patients: FIGO Stage, Biomarkers and Molecular Classification
por: Kasius, Jenneke C., et al.
Publicado: (2021)

Combined score of pretreatment platelet count and CA125 level (PLT-CA125) stratified prognosis in patients with FIGO stage IV epithelial ovarian cancer
por: Chen, Jie-Ping, et al.
Publicado: (2019)

Differences in Clinical and Biological Features Between Type I and Type II Tumors in FIGO Stages I-II Epithelial Ovarian Carcinoma
por: Skirnisdottir, Ingiridur, et al.
Publicado: (2015)

Molecular Classification of Endometrial Cancer and the 2023 FIGO Staging: Exploring the Challenges and Opportunities for Pathologists
por: Zheng, Wenxin
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_bujmgpepcklo9nm3g4ejgv18ga